Masultab (Amisulpride)

Amisulpride is an atypical antipsychotic that modulates dopaminergic pathways in psychotic disorders.

• Schizophrenia: reduces positive symptoms such as hallucinations and delusions, improves negative symptoms like social withdrawal, and enhances treatment adherence.
• Acute Psychotic Episodes: rapidly alleviates severe psychotic symptoms, facilitating stabilization of acute crises.
• Schizoaffective Disorder: helps control both mood and psychotic components, supporting overall functional improvement.
• Bipolar Disorder with Psychotic Features: mitigates psychotic symptoms when present, complementing mood stabilizers.

• Amisulpride selectively blocks dopamine D2 and D3 receptors. At low doses it preferentially antagonises presynaptic autoreceptors, increasing dopamine release, which can improve negative symptoms. At higher doses it blocks postsynaptic receptors, reducing dopaminergic transmission and alleviating positive psychotic symptoms. The antagonism is reversible and dose‑dependent, and the compound exhibits minimal activity at serotonergic or adrenergic receptors, contributing to its relatively selective side‑effect profile.

Amisulpride may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Dizziness: sensation of light‑headedness or imbalance.
• Nausea: upset stomach often with mild vomiting.
• Weight gain: gradual increase in body weight.
• Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects

• Neuroleptic malignant syndrome: life‑threatening reaction with fever, muscle rigidity, autonomic instability.
• Tardive dyskinesia: persistent involuntary movements, especially of the face and tongue.
• QT interval prolongation: cardiac electrical disturbance that may lead to arrhythmia.

When prescribing Amisulpride, clinicians should observe several safety considerations to minimize risk.

• Monitor blood pressure: watch for orthostatic hypotension, especially at treatment initiation.
• Assess extrapyramidal symptoms: evaluate for tremor, rigidity, or akathisia regularly.
• Evaluate cardiac function: obtain ECG to detect QT prolongation in at‑risk patients.
• Use caution in renal or hepatic impairment: dose adjustment may be required.
• Avoid in patients with known hypersensitivity to Amisulpride or excipients.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Amisulpride can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Co‑administration with other dopamine antagonists: may increase risk of extrapyramidal symptoms.
• Concomitant use of QT‑prolonging drugs (e.g., quinidine, haloperidol): can exacerbate cardiac arrhythmia risk.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise plasma levels of Amisulpride.

Moderate Interactions (Monitor Closely)

• Anticholinergic agents: may mask anticholinergic side effects, requiring dose adjustments.
• CNS depressants (e.g., benzodiazepines, alcohol): can enhance sedation and dizziness.